life science pharma News
-
mRNA/LNP technology platform company etherna names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board
Sagaert’s CEO appointment follows his successful interim period implementing etherna’s new partnership-driven business strategy. Sagaert joined etherna in 2017 and brings extensive operational and strategic experience in the life sciences industry. Dekkers, who is the founder of investment and advisory firm Novalis Capital Partners LLC and former CEO of Bayer AG and Thermo ...
By eTheRNA
-
Anavex Life Sciences and Ariana Pharma present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference
Ariana Pharma, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 International Conference. MDS-UPDRS Total score improved significantly for patients treated with ANAVEX®2-73 high oral once-daily dose compared to ...
-
Biocom Names Winners of Third Annual Life Science Catalyst Awards
Biocom, the association representing the California life science industry, today announced the winners of its third annual Life Science Catalyst Awards. The program celebrates up-and-coming entrepreneurs, academics, investors, corporate leaders and business advisers who are making a lasting and positive mark on Southern California’s life science industry prior to reaching their 40th ...
-
Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement
Offer price increased from €39.00 to €43.00 per QIAGEN share in cash Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. ...
-
Third Pole Therapeutics Names Bill Athenson New CEO
Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, has named seasoned healthcare executive Bill Athenson as its new Chief Executive Officer, the company announced today. David Zapol, Third Pole’s founding CEO, will continue providing strategic counsel to Third Pole. Athenson joins Third Pole building on the ...
-
DSM reports very strong Q1 2011 continuing its positive momentum
Q1 EBITDA from continuing operations up 14% to € 325 million Life Sciences results driven by ongoing good performance in Nutrition Materials Sciences posts solid results reflecting volume gains and pricing strength EPS € 0.91, 30% higher also due to a lower tax rateMartek integration underway; EBITDA in line with expectations2011 is expected to be a strong year for ...
-
Thermo Fisher Scientific Recognized with Six CMO Leadership Awards
Thermo Fisher Scientific, the world leader in serving science, today announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. Thermo Fisher won across all six categories, including: Capabilities, Compatibility, Expertise, ...
-
Optibrium expands operations in North America for AI and computational drug discovery technologies
Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, today announced the opening of its US subsidiary, Optibrium Inc., and the promotion of Dr Tamsin Mansley to President of the new subsidiary to lead its US-based team and business operations. The opening strengthens the Company’s direct sales, technical and application support for new ...
-
Pluto Biosciences Launches Cloud-based Collaborative Life Sciences Platform for Academia Biotech and Pharma Organizations
Pluto Biosciences, a biotech software startup, launched its cloud-based, collaborative life sciences platform that leverages technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University. The Pluto platform simplifies secure, collaborative data sharing and bioinformatics analysis for academic, biotech, and pharmaceutical organizations. The Pluto platform ...
-
Invizius appoints industry heavyweights
Invizius, the University of Edinburgh spin-out which is developing potentially lifesaving products for dialysis patients, has made four high-profile appointments as it prepares to enter the next stage of its development. The new directors all have international experience in leading pharma and life sciences businesses. Their arrival follows the recent £2.75m investment in Invizius by a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you